Actos—pioglitazone—is one of the best-selling drugs in the United States, used in the treatment of Type 2 diabetes. Actos gained FDA approval some thirteen years ago, and despite numerous reports of adverse health symptoms linked to Actos.

Actos is a drug frequently prescribed for those with Type 2 diabetes. Takeda, a Japanese pharmaceutical company, began manufacturing Actos in 1999.

Actos (pioglitazone) is a prescription drug used in the treatment of Type 2 Diabetes. Approved in 1999, the drug has been on the market for over thirteen years, and at one time was considered a safe alternative to the drug Avandia (which was targeted for contributing to adverse cardiovascular events in users).

Despite these negative reports, the sales of Actos continued to skyrocket with its manufacturer, Takeda, netting over $3 billion dollars for the sale of Actos in 2010 alone.

Actos (pioglitazone hydrochloride) is a prescription drug used in the treatment of ‘Type 2’ Diabetes and was approved for use some thirteen years ago.

Actos is a prescription drug manufactured by Takeda, a Japanese pharmaceutical corporation, over thirteen years ago and is used in the treatment of Type 2 diabetes. While there were many adverse health issues reported among users of Actos

This article continues the discussion of the Kaiser Permanente study, conducted over a period of ten years which attempted to determine the risk of bladder cancer in those taking the Type 2 diabetes drug, Actos. Incomplete or missing data were considered potential confounders, or variables which could change the results of the study.

This two-part article series will detail a ten-year study between 1997 and 2008 done to determine the relative risk of developing bladder cancer among diabetic patients who were being treated with the drug Actos in an effort to control their diabetic symptoms. After receiving adverse reports regarding the safety of Actos, the FDA requested the manufacturer of Actos, Takeda, conduct a safety study in order to determine whether Actos therapy directly increased the risk of bladder cancer.

Continuing from part one which details the particulars of the pending Actos lawsuits, part two will talk about the MDL case as well as case law which may pertain to Actos suits. The discussion at a recent attorney’s conference regarding Actos litigation discussed the highlights of the MDL Actos case.

Nearly thirteen years ago a new diabetic drug, Actos, was approved for the treatment of Type 2 diabetes. Takeda, the Japanese manufacturer of Actos collaborated with Eli Lilly to release the drug in the United States at the time. At the same time Actos was approved, a close competitor, Avandia, was also approved.